<DOC>
	<DOCNO>NCT00331955</DOCNO>
	<brief_summary>This phase I trial study side effect best dose vorinostat give together doxorubicin treat patient metastatic locally advanced solid tumor . Vorinostat may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , doxorubicin , work different way stop growth tumor cell , either kill cell stop dividing . Vorinostat may help doxorubicin work well make tumor cell sensitive drug .</brief_summary>
	<brief_title>Vorinostat Doxorubicin Treating Patients With Metastatic Locally Advanced Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine safety tolerability vorinostat ( SAHA ) doxorubicin hydrochloride patient metastatic locally advanced solid tumor . II . Determine maximum tolerate dose vorinostat administer doxorubicin hydrochloride patient treat regimen . SECONDARY OBJECTIVES : I . Determine response rate ( complete response [ CR ] partial response [ PR ] ) clinical benefit rate ( CR , PR , stable disease &gt; 12 week ) patient treat regimen . II . Determine pharmacokinetics pharmacodynamics vorinostat doxorubicin hydrochloride interaction . III . Determine effect vorinostat histone acetylation peripheral blood mononuclear cell tumor . IV . Determine effect vorinostat DNA damage induce doxorubicin hydrochloride function topoisomerase II expression . V. Determine effect vorinostat gene protein crucial maintenance chromatin structure . OUTLINE : This non-randomized , open-label , dose-escalation study vorinostat . Patients receive oral vorinostat twice daily 5 dos day 1-3 , 8-10 , 15-17 doxorubicin hydrochloride IV day 3 , 10 , 17 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Patients respond stable disease 6 course treatment may continue receive vorinostat alone absence disease progression . Cohorts 3-6 patient receive escalate dos vorinostat maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Up to15 patient treat MTD . Mandatory biopsy require patient . Patients undergo blood collection tumor biopsy periodically study pharmacologic , pharmacokinetic , pharmacodynamic , biomarker correlative study . After completion study treatment , patient follow least 30 day . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Histologically cytologically confirm solid tumor malignancy curative therapy exist Measurable evaluable disease tumor accessible biopsy determine CT scan ultrasound Skin , lymph node , chest wall lesion allow provided measurement confirm 2 independent health care professionals No uncontrolled CNS metastases Patients stable CNS metastasis ( either surgically resect , treat gamma knife , stable 3 month wholebrain radiotherapy document MRI within past 4 week ) eligible Willing undergo pre postvorinostat tumor biopsy Life expectancy ≥ 3 month ECOG performance status 02 WBC &gt; 3,000/mm^3 Absolute neutrophil count &gt; 1,500/mm^3 Hemoglobin &gt; 9.0 g/dL Platelet count &gt; 100,000/mm^3 ( transfusion independent ) Creatinine ≤ 2.0 mg/mL Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 1.5 time ULN LVEF &gt; 50 % Fertile patient must use effective contraception 6 month completion study treatment Negative pregnancy test Not pregnant nursing No significant active infection ( e.g. , pneumonia , cellulitis , wound abscess ) No history cardiac failure No history long QT syndrome ( QTc &gt; 470 msec ) No history ventricular tachycardia fibrillation No history seizures No history allergic reaction attribute compound similar chemical biological composition vorinostat agent use study More 3 week since prior chemotherapy radiotherapy ( 2 week weekly regimen ) More 2 week since prior valproic acid histone deacetylase inhibitors No prior anthracycline exposure No concurrent chemotherapy No concurrent hormonal therapy except maintenance therapy luteinizinghormone releasinghormone agonists No concurrent antiarrhythmics No concurrent steroid control brain metastasis No concurrent colonystimulating factor ( e.g. , filgrastim [ GCSF ] sargramostim [ GMCSF ] ) first course study treatment No concurrent investigational agent primary disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>